Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)-Reference-Cited by-同舟云学术

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Published:2015-07 Issue:1 Volume:73 Page:37-49
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Papp Kim,Reich Kristian,Leonardi Craig L.,Kircik Leon,Chimenti Sergio^ORCID,Langley Richard G.B.,Hu ChiaChi,Stevens Randall M.,Day Robert M.^ORCID,Gordon Kenneth B.,Korman Neil J.,Griffiths Christopher E.M.

Funder

Abbott

Acambis

Allergan

Amgen

Assos Pharma

Astellas Pharma US

Asubio

Berlex Laboratories

Biogen Idec

Biolife

Biopelle

Breckinridge Pharma

Colbar

Celgene

Centocor

CollaGenex

Combinatrix

Connetics

Coria

Dermik Laboratories

Dow Pharmaceutical Sciences

Dusa

Embil Pharmaceuticals

EOS

Ferndale Laboratories

Galderma

Genentech

GlaxoSmithKline

Health Point

Intendis

Innovail

Johnson & Johnson

Laboratory Skin Care

LEO Pharma

Medical International Technologies

Merck

Medicis Pharmaceutical

Merz

Nano Bio

Novartis

Nucryst Pharmaceuticals

Obagi

Onset

OrthoNeutrogena

Promius

QLT

PharmaDerm

Pfizer

Quatrix

Serono

SkinMedica

Stiefel, TolerRx

Triax

Valeant Pharmaceuticals Intl

Warner-Chilcott

ZAGE

Janssen

AbbVie

Lilly

Ortho-McNeil-Janssen Pharmaceuticals

Actelion

LEO Pharma

Merck Sharp & Dohme

Sandoz

UCB

National Institute for Health Research

Publisher

Elsevier BV

Subject

Dermatology

Reference19 articles.

1. Keynote review: phosphodiesterase-4 as a therapeutic target;Houslay;Drug Discov Today,2005

2. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis;Schafer;Biochem Pharmacol,2012

3. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast;Gottlieb;Curr Med Res Opin,2008

4. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study;Gottlieb;J Drugs Dermatol,2013

5. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis;Lambert;Am J Respir Cell Mol Biol,2014

Cited by 475 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis;Clinical Pharmacokinetics;2024-01-27

2. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents;Pharmaceutics;2024-01-15

3. Evolution of patient demographics, baseline clinical characteristics and outcomes in Phase 3 trials of biologics (TNFi, IL12/23i, IL17i, IL23i), PDE4i and TYK2i for psoriasis;JEADV Clinical Practice;2024-01-05

4. ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study;European Journal of Pharmacology;2024-01

5. Phosphodiesterase-4 Inhibition in the Management of Psoriasis;Pharmaceutics;2023-12-22